Publikationen


  • Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores Cancers 2021, 13(4), 844; 
    Riecke K, Müller V, Weide R, Schmidt M, Park-Simon T-W, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Laakmann E, Thill M, Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Witzel I
  • Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. Cancers (2020); 12(10): 2787. doi: 10.3390/cancers12102787.
    Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Riecke K, Thill M, Fasching PA, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V.
  • Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement BMC Immun (2020) 21:39. K
    Weide R , Schnell R, Schardt C, Koenigsmann M, Otremba B, Zahn M-O, Wierecky J, Braun U, Hensel M, Klausmann M, Fleckenstein D, Ehscheidt P, Feiten S
  • Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). Hemasphere (2020); 4(1): e336. doi: 10.1097/HS9.0000000000000336.
    Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, De Silva N, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Herling M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Böttcher S, Stilgenbauer S, Fink AM, Hallek M, Eichhorst B.
  • Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors. J Oncol Pharm Pract (2020). doi: 10.1177/1078155220946381 [Online ahead of print]. 
    Rosentreter J, Alt J, Fried M, Chakupurakal G, Stratmann J, Krämer I.
  • DNVF Memorandum Versorgungsforschung in der Onkologie. Das Gesundheitswesen (2020). doi: 10.1055/a-1191-3759. 
    Kowalski C, Albert U-S, Baumann W, Carl G, Ernstmann N, Hermes-Moll K, Fallenberg E A, Feick G, Feiten S, Härter M, Heidt V, Heuser C, Hübner J, Joos S, Katalinic A, Kempkens Ö, Kerek-Bodden H, Klinkhammer-Schalke M, Koller M, Langer T, Lehner B, Lux M P, Maatouk I, Pfaff H, Ratsch B, Schach S, Scholl I, Skoetz N, Voltz R, Wiskemann J, Inwald E C.
  • Infektionskontrolle bei hämatologischen und onkologischen Neoplasien. TumorDiagn u Ther (2020); 41: 299-301. https://doi.org/10.1055/a-1132-1156. 
    Weide R
  • Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017. Leuk Lymphoma (2019); 61(3): 557-566. https://doi.org/10.1080/10428194.2019.1680840. 
    Weide R, Feiten S, Chakupurakal G, Friesenhahn V, Kleboth K, Köppler H, Lutschkin J, van Roye C, Thomalla J, Heymanns J.
  • Response to the letter to the Editor concerning our article ‚High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany‘ Support Care Cancer (2019).
    Feiten S, Chakupurakal G, Feustel HP, Maasberg M, Otremba B, Ehscheidt P, Hensel M, Hansen R, Weide R.
  • Treatment and Outcome of Patients with Palliative Non-small Cell Lung Cancer (NSCLC) in Routine Outpatient Care Over Two Decades. J Cancer Sci Ther/Vol.11.5 167(2019), Vol 11(5) 
    Chakupurakal G, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, Lutschkin J, Thomalla J, van Roye C, Weide R.
  • Entfernungen überbrücken – Telemedizin. In: Jünger J. (Hrsg.) 2018. Ärztliche Kommunikation: Praxisbuch zum Masterplan Medizinstudium 2020, Stuttgart: Schattauer, S. 570 – 575. 
    Vitinius F, Rarek M, Peltzer S, Heymanns J.
  • High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany. Support Care Cancer (2019), 27:4265–4271. doi: 10.1007/s00520-019-04721-4 
    Feiten S, Chakupurakal G, Feustel HP, Maasberg M, Otremba B, Ehscheidt P, Hensel M, Hansen R, Weide R. 
  • Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2019;106:181-192.
    Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching PA, Nekljudova V, von Minckwitz G, Loibl S 
  • Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2018 Dec 4. pii: haematol.2018.206797. doi: 10.3324/haematol.2018.206797. [Epub ahead of print] 
    Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.
  • Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer. 2018;102:1-9.
    Witzel I, Laakmann E, Weide R, Neunhöffer T, Park-Simon TJ, Schmidt M, Fasching PA, Hesse T, Polasik A, Mohrmann S, Würschmidt F, Schem C, Bechtner C, Würstlein R, Fehm T, Möbus V, Burchardi N, Loibl S, Müller V.
  • Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398-2406.
    Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. 
  • Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
    Tortorici MA, Lawo JP, Weide R, Jochems J, Puli S, Hofmann J, Pfruender D, Rojavin MA Int Immunopharmacol 2018; 66:119-126.
  • Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices
    Chakupurakal G, Feiten S, Burkhard O, Reiser M, Ehscheidt P, Weide R Oncol Res Treat 2017;40:784-788.
  • Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
    Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J Leukemia 2017;31(11):2398-2406.
  • Versorgungsforschung in onkologischen Schwerpunktpraxen in Deutschland
    Weide R Der Onkologe 2017; 23:1-6
  • Standard of care of patients with Chronic Myeloid Leukemia (CML) treated in community based oncology group practices between 2001-2015 in Rhineland-Palatinate (Germany)
    Weide R, Rendenbach B, Grundheber M, Burkhard O, Behringer J, Maasberg M, Ehscheidt P, Strehl JW, Hansen R, Feiten S Applied Cancer Research 2017;37:26
  • Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma
    Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H. TumorDiagn u Ther 2016;37:393-397
  • Follow-up Reality for Breast Cancer Patients – Standardised Survey of Patients and Physicians and Analysis of Treatment Data
    Feiten S, Dünnebacke J, Friesenhahn V, Heymanns J, Köppler H, Meister R, Thomalla J, van Roye C, Wey D, Weide R Geburtshilfe Frauenheilkd 2016; 76(05): 557-563
  • Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice
    Feiten S, Weide R, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, van Roye C, Thomalla J SpringerPlus (2016) 5:270
  • Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014
    Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H. Oncol Res Treat 2016;39:41-44.
  • Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma
    Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.Dtsch Med Wochenschr 2015;140(19):e201-6
  • NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim – First Interim Analysis
    Kurbacher C.M., Fietz T, Diel I, Egert, Hurtz H-J, Lück A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Weißenborn G, Steffens C, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein R W Oncol Res Treat 2015;38:221–229
  • Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive Tumors.
    Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H SpringerPlus 2014 3:535.
  • Breast cancer morbidity – questionnaire survey of patients on the long term effects of disease and adjuvant therapy.
    Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R Dtsch Arztebl Int 2014; 111: 537-44.
  • The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison.
    Herth I, Dietrich S, Benner A, Hegenbart U, Rieger M, Stadtherr P, Bondong A, Tran TH, Weide R, Hensel M, Knauf W, Franz-Werner J, Welslau M, Procaccianti M, Görner M, Meissner J, Luft T, Schönland S, Witzens-Harig M, Zenz T, Ho AD, Dreger P Ann Oncol. 2014;25(1):200-6.
  • Psychosocial Distress in Caregivers of Patients with a Metastatic Solid Tumor in Routine Care: A Survey in a Community Based Oncology Group Practice in Germany.
    Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, Mergenthaler U, Thomalla J, van Roye C & Weide R Cancer and Clinical Oncology 2013,2(2):1-10.
  • Improved Survival of HER2-Positive Metastatic Breast Cancer in Routine Care
    Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, Mergenthaler U, van Roye C & Köppler H Cancer and Clinical Oncology 2013, Vol. 2 (1):17-27
  • Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
    Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C & Köppler H Leuk Lymphoma. 2013;54(8):1640-6
  • Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
    Köppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, Schmitz S, Weide R, Weiß J, Hallek M; GCLLSG. Br J Haematol. 2012;158(2):238-41.
  • Identifying Caregivers and Their Meaning for Patients with Metastatic Solid Tumours in Routine Care: A Survey at a Community-Based Oncology Group Practice in Germany
    Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Mergenthaler U, Thomalla J, van Roye C & Köppler H Cancer and Clinical Oncology. 2012; 1(1): 41-51
  • Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
    Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer K-A, Schlenk R, Ganser A, Hofmann W-K, Aul C, Krieger O, Kündgen A, Haas R, Hasford J and Giagounidis A Leukemia 2012: doi:10.1038/leu.2011.391
  • Evaluation of psychosocial distress in patients treated in a community-based oncology group practice in Germany
    Mergenthaler U, Heymanns J, Köppler H, Thomalla J, van Roye C, Schenk J, Weide R. Ann Oncol. 2011;22(4):931-8
  • Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
    Weide R, Köppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS. J Cancer Res Ther.2010 Jan-Mar;6(1):31-5
  • The impact of new treatment options for advanced colorectal cancer on routine care: Results of a retrospective analysis of 206 consecutive patients treated in a community based oncology group practice
    Köppler H, Heymanns J, Thomalla J, Kleboth K, Weide R. Eur J Cancer Care 2010;19(6):795-802 Interdisziplinäre ambulante Versorgung Schmitz S, Heymanns J. Der Onkologe 2009 Oct;15:1065-1069
  • Bendamustine/Mitoxantrone/Rituximab (BMR): A short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia (CLL)
    Weide R, Mergenthaler U, Friesenhahn V, Kleboth K, Heymanns J, Thomalla J, Köppler H. Leuk Lymphoma. 2009 Sep;50(9):1468-1474
  • Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.
    Rhiem K, Wappenschmidt B, Bosse K, Köppler H, Tutt AN, Schmutzler RK. Clin Oncol (R Coll Radiol). 2009 Aug;21(6):448-50. Epub 2009 Feb 26.
  • Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
    Diel IJ, Weide R, Köppler H, Antràs L, Smith M, Green J, Wintfeld N, Neary M, Duh MS. Support Care Cancer. 2009 Jun;17(6):719-25. Epub 2008 Dec 17.
  • CT-guided percutaneous core needle biopsy in oncology outpatients: sensitivity, specificity, complications.
    Steil S, Zerwas S, Moos G, Bittinger F, Hansen T, Mergenthaler U, Weide R. Onkologie. 2009 May;32(5):254-8. Epub 2009 Apr 22.
  • Improved survival of patients with metastatic breast cancer in routine care: results of a retrospective study in a community-based oncology group practice 1995-2005.
    Weide R, Mergenthaler U, Pandorf A, Arndt H, Heymanns J, Thomalla J, Köppler H. Onkologie. 2009 Mar;32(3):107-13. Epub 2009 Feb 13.
  • Treatment of Advanced Non Small Cell Lung Cancer in Routine Care: A Retrospective Analysis of 212 Consecutive Patients Treated in a Community Based Oncology Group Practice
    Koeppler H, Heymanns J, Thomalla J,Kleboth K, Mergenthaler U, Weide R. Clinical Medicine: Oncology 2009:3 63-70
  • Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
    Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, Fries S, Knoblich J, Köchling G, Laubenstein HP, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T. Haematologica. 2009 Jan;94(1):141-4. Epub 2008 Nov 23.
  • Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma.
    Weide R. Ther Clin Risk Manag. 2008 Aug;4(4):727-32.
  • Ovarian cancer treatment reality in northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival.
    Weide R, Arndt M, Pandorf A, Heymanns J, Thomalla J, Köppler H. Onkologie. 2007 Dec;30(12):611-7.
  • High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M; German Low Grade Lymphoma Study Group. Leuk Lymphoma. 2007 Jul;48(7):1299-306.
Stellenangebote